The names “TB-500” and “thymosin beta-4” are used almost interchangeably across research-peptide listings, and that conflation hides a real structural distinction. Thymosin β-4 (TB-4) is a full, naturally occurring protein. TB-500 is a much shorter synthetic peptide that vendors describe as corresponding to one region of that protein. They are related, but they are not the same molecule. This article walks through what each compound is at the chemical level, the actin-binding mechanism they share, and what the published literature has actually measured.
What thymosin β-4 is: the full 43-amino-acid protein
Thymosin β-4 is a small, naturally occurring 43-amino-acid peptide — an acidic, heat-stable molecule of roughly 5 kDa that is widely distributed in cells and tissues. Its defining biochemical role is as the principal G-actin–sequestering peptide: it binds free actin monomers (G-actin) and holds them in reserve, keeping them from assembling into actin filaments (F-actin) until they are needed.
That sequestering function has been characterized in detail. Early work established that purified thymosin β-4 forms a 1:1 complex with an actin monomer and inhibits its polymerization (Safer et al., J Biol Chem, 1991). Cell-level work in human polymorphonuclear leukocytes then measured that thymosin β-4 was abundant enough to sequester the majority of available G-actin in resting cells (Cassimeris et al., J Cell Biol, 1992), and a structural study determined that it sequesters by effectively capping both ends of the actin monomer, preventing its incorporation into a growing filament (Irobi et al., EMBO J, 2004). The key takeaway: thymosin β-4 is a complete, defined protein with a well-mapped interaction with actin — not a fragment of anything.
What “TB-500” is: a synthetic fragment of the actin-binding region
“TB-500” is a synthetic peptide, and the name does not denote the full thymosin β-4 protein. In the analytical literature, the material sold as TB-500 was identified as the N-terminal acetylated 17–23 fragment of human thymosin β-4, with the sequence Ac-LKKTETQ (Esposito et al., Drug Test Anal, 2012). That places it squarely inside thymosin β-4’s actin-binding region: the conserved motif LKKTET begins at residue 17 of the 43-amino-acid sequence and is the segment most often referred to as the protein’s actin-binding motif.
So the relationship is one of part to whole:
- Thymosin β-4 — the entire 43-amino-acid protein.
- TB-500 — a short synthetic peptide (Ac-LKKTETQ) corresponding to the central actin-binding region (around residues 17–23), with an N-terminal acetyl group that the natural protein does not carry at that position.
So “TB-500 vs thymosin beta-4” is not a comparison of two unrelated compounds, but of a full protein and a fragment derived from one of its functional domains.
Why the names get conflated — and why that’s imprecise
Research-peptide vendors frequently label TB-500 simply as “thymosin beta-4,” or list the two as a single product. The conflation is understandable, since the fragment comes from the protein’s most-studied region, but it is chemically imprecise for three reasons:
- Size. One is a 43-amino-acid protein; the other is a seven-residue peptide. They are not the same molecule and do not share the same molecular weight.
- Structure. TB-500 carries an N-terminal acetyl modification (the “Ac-” in Ac-LKKTETQ); it is not simply “a piece of” the unmodified protein clipped out intact.
- Published evidence. The two have not been studied to the same extent. Most of the foundational actin-biology literature was generated using the full thymosin β-4 protein, not the seven-residue fragment.
The accurate framing is that TB-500 is a synthetic fragment/analog of thymosin β-4’s actin-binding region, used loosely in commerce to stand in for the parent protein. Our combined listing for TB-500 / Thymosin Beta-4 reflects that the two names travel together in the research-supply market even though they describe different molecules.
The shared mechanism: the actin-binding motif
What ties the fragment to the full protein is the LKKTET motif. Because this motif is the part of thymosin β-4 most directly involved in contacting actin, a fragment built around it retains the feature central to the parent protein’s actin interaction.
The functional weight of that motif has been measured directly. In one study, an isolated peptide containing the seven-amino-acid actin-binding motif was reported to reproduce the angiogenic activity seen with the full thymosin β-4 protein in the assays used, while fragments lacking parts of that motif were inactive in those same models (Philp et al., FASEB J, 2003). In the models tested, the motif — not the rest of the sequence — carried the measured activity, which is what makes the actin-binding region the logical basis for a derived peptide.
It is worth stating plainly what this does and does not establish. These studies characterize a molecular interaction with actin measured in specific laboratory models. They do not establish that the fragment and the full protein are interchangeable across every endpoint, and the deeper actin-sequestering characterization — the 1:1 stoichiometry, the monomer-capping structure — was done on the complete protein.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin β-4 is the full 43-amino-acid protein. TB-500 is a synthetic peptide that corresponds to a short fragment of that protein — the acetylated 17–23 region (Ac-LKKTETQ) containing its actin-binding motif. They are related but chemically distinct, and vendors often use the two names loosely as if they were one product.
Why is TB-500 called a “fragment” of thymosin beta-4?
Because its sequence matches only a small section of the full protein. The material identified as TB-500 was characterized as the N-terminal acetylated 17–23 fragment of human thymosin β-4 (Esposito et al., 2012), whereas the parent protein is 43 amino acids long.
What is the LKKTET motif?
LKKTET is a short, conserved sequence beginning at residue 17 of thymosin β-4 that is commonly described as the protein’s actin-binding motif. It is the part of the protein most directly involved in contacting actin, which is why a derived fragment is built around it.
How does thymosin beta-4 interact with actin?
Published research characterized thymosin β-4 as the principal G-actin–sequestering peptide: it forms a 1:1 complex with an actin monomer (Safer et al., 1991) and, structurally, caps both ends of the monomer to keep it out of filaments (Irobi et al., 2004). In resting human leukocytes it was measured as abundant enough to sequester most available G-actin (Cassimeris et al., 1992).
Have TB-500 and thymosin beta-4 been studied the same amount?
No. Most of the foundational actin-biology literature used the full thymosin β-4 protein. One study reported that an isolated peptide containing the seven-amino-acid actin-binding motif reproduced the angiogenic activity of the full protein in the models tested (Philp et al., 2003), but the deeper mechanistic characterization was done on the complete protein.
Why do vendors list them together?
Because the fragment is derived from the most-studied region of the protein, the research-supply market uses the names interchangeably. The precise framing: TB-500 is a synthetic fragment or analog of thymosin β-4’s actin-binding region, not the full protein.
References
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012. PMID: 22962027.
- Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry. 1991. PMID: 1999398.
- Cassimeris L, et al. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. Journal of Cell Biology. 1992. PMID: 1447300.
- Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO Journal. 2004. PMID: 15329672.
- Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003. PMID: 14500546.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
